Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis

Bhavana Bhagya Rao, Bret Lashner, Kris V. Kowdley

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

The presence of concomitant primary sclerosing cholangitis (PSC) with inflammatory bowel disease (IBD) represents a distinct disease phenotype that carries a higher risk of colorectal cancer (CRC) than the average IBD patient. Given that liver transplantation (LT) is the only treatment that offers a survival benefit in PSC patients with hepatic dysfunction, management decisions in IBD patients' post-LT for PSC are frequently encountered. One such consideration is the risk of CRC in this immunosuppressed cohort. With most studies showing an increased risk of CRC post-LT in these IBD patients, a closer look at the associated risk factors of CRC and the adopted surveillance strategies in this subset of patients is warranted. Low-dose ursodeoxycholic acid has shown a potential chemopreventive effect in PSC-IBD patients pre-LT; however, a favorable effect remains to be seen in post-LT group. Also, further studies are necessary to assess the benefit of 5 aminosalicylate therapy. Annual surveillance colonoscopy in the post-LT period is recommended for PSC-IBD patients subset given their high risk for CRC.

Original languageEnglish
Pages (from-to)269-276
Number of pages8
JournalInflammatory Bowel Diseases
Volume24
Issue number2
DOIs
StatePublished - 18 Jan 2018
Externally publishedYes

Keywords

  • 5 aminosalicylates
  • inflammatory bowel disease
  • liver transplantation
  • primary sclerosing cholangitis
  • ursodeoxycholic acid

Fingerprint

Dive into the research topics of 'Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis'. Together they form a unique fingerprint.

Cite this